Background
Tertiary Lymphoid Structures (TLS) are critical components of the tumor microenvironment and may influence the efficacy of immune checkpoint inhibitors (ICIs) 1,2. High tumor mutational burden (TMB) and microsatellite instability-high (MSI-High) are now established biomarkers approved to guide treatment with ICIs such as pembrolizumab. This study explores the impact of TLS status on the outcomes of patients with these biomarker-positive profiles undergoing pembrolizumab treatment.
Download Publication